Pharvaris (PHVS) Dividends Paid - Common (2020 - 2026)
Pharvaris' (PHVS) quarterly Dividends Paid - Common came in at $289.1 million in Q1 2026, up 16.22% YoY from $248.8 million in Q1 2025, and down 100.0% on a QoQ basis from $339526.5 billion in Q4 2025.
Pharvaris (PHVS) Dividends Paid - Common (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Dividends Paid - Common data on file, last reported at $289.1 million in Q1 2026.
- Quarterly Dividends Paid - Common rose 16.22% year-over-year to $289.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $339526.9 billion (up 13.18% YoY) and the FY2025 annual result came in at $329542.1 billion, up 8.46% from the prior year.
- Dividends Paid - Common eased to $289.1 million in Q1 2026, from $339526.5 billion in the prior quarter.
- In the past five years, Dividends Paid - Common ranged from a high of $420941.6 billion in Q4 2023 to a low of -$195063.0 billion in Q3 2023.
- A 5-year average of $72095.7 billion and a median of $218.6 million in 2022 frame the typical range for Dividends Paid - Common.
- The widest YoY moves for Dividends Paid - Common: up 2767120105.74% in 2023, down 5295053077.99% in 2023.
- Tracing PHVS's Dividends Paid - Common over 5 years: stood at $165114.0 billion in 2022, then jumped by 154.94% to $420941.6 billion in 2023, then slipped by 28.73% to $299984.4 billion in 2024, then rose by 13.18% to $339526.5 billion in 2025, then tumbled by 100.0% to $289.1 million in 2026.
- The last three Dividends Paid - Common figures came in at $289.1 million (Q1 2026), $339526.5 billion (Q4 2025), and $151.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 96.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 34.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.13 Mn |
| Mar 31, 2026 | 289.13 Mn |
| Dec 31, 2025 | 339,526.53 Bn |
| Dec 31, 2025 | 339,526.53 Bn |
| Sep 30, 2025 | 151.64 Mn |
| Sep 30, 2025 | 151.64 Mn |
| Jun 30, 2025 | -41.80 Mn |
| Jun 30, 2025 | -41.80 Mn |
| Mar 31, 2025 | 248.77 Mn |
| Mar 31, 2025 | 248.77 Mn |
| Dec 31, 2024 | 299,984.36 Bn |
| Dec 31, 2024 | 299,984.36 Bn |
| Sep 30, 2024 | -42.15 Mn |
| Sep 30, 2024 | -42.15 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Jun 30, 2024 | -26.67 Mn |
| Mar 31, 2024 | 400.15 Mn |
| Mar 31, 2024 | 400.15 Mn |
| Dec 31, 2023 | 420,941.56 Bn |
| Dec 31, 2023 | 420,941.56 Bn |